ATOS · Insider Trading
Atossa Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ATOS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | H. Lawrence Remmel | Director | A | +10,000 | — |
| 2026-05-14 | Jonathan Finn | Director | A | +10,000 | — |
| 2026-05-14 | Richard I Steinhart | Director | A | +10,000 | — |
| 2026-05-14 | Stephen J Galli | Director | A | +10,000 | — |
| 2026-05-14 | Shu-Chih Chen | Director | A | +10,000 | — |
| 2026-05-14 | Tessa Cigler | Director | A | +10,000 | — |
| 2026-03-30 | Mark James Daniel | Chief Financial Officer | A | +63,000 | — |
| 2026-01-30 | Steven C Quay | President & CEO | A | +331,674 | — |
| 2026-01-22 | Steven C Quay | President & CEO | A | +325,203 | — |
| 2025-10-21 | Mark James Daniel | Chief Financial Officer | A | +578,000 deriv. | — |
| 2025-05-22 | Steven C Quay | President & CEO | Buy | +11,239 | +$9.89K |
| 2025-05-16 | Tessa Cigler | Director | A | +125,000 deriv. | — |
| 2025-05-16 | Stephen J Galli | Director | A | +125,000 deriv. | — |
| 2025-05-16 | Richard I Steinhart | Director | A | +125,000 deriv. | — |
| 2025-05-16 | Shu-Chih Chen | Director | A | +125,000 deriv. | — |
| 2025-05-16 | Steven C Quay | President & CEO | A | +1,366,062 deriv. | — |
| 2025-05-16 | Heather Rees | Chief Financial Officer | A | +543,785 deriv. | — |
| 2025-05-16 | Jonathan Finn | Director | A | +125,000 deriv. | — |
| 2025-05-16 | H. Lawrence Remmel | Director | A | +125,000 deriv. | — |
| 2025-03-28 | H. Lawrence Remmel | Director | Buy | +10,000 | +$7.00K |
| 2024-07-01 | Jonathan Finn | Director | A | +125,000 deriv. | — |
| 2024-07-01 | H. Lawrence Remmel | Director | A | +125,000 deriv. | — |
| 2024-07-01 | Heather Rees | SVP, Finance and Accounting | A | +577,700 deriv. | — |
| 2024-07-01 | Tessa Cigler | Director | A | +125,000 deriv. | — |
| 2024-07-01 | Richard I Steinhart | Director | A | +125,000 deriv. | — |
| 2024-07-01 | Stephen J Galli | Director | A | +125,000 deriv. | — |
| 2024-07-01 | Shu-Chih Chen | Director | A | +125,000 deriv. | — |
| 2024-07-01 | Steven C Quay | President & CEO | A | +1,795,100 deriv. | — |
| 2024-04-11 | Jonathan Finn | Director | Buy | +25,000 | +$44.25K |
| 2024-03-14 | Tessa Cigler | Director | A | +20,834 deriv. | — |
| 2023-11-17 | Gregory L Weaver | Former EVP, CFO, & Director | Sell | −50,000 | −$32.50K |
| 2023-11-15 | Jonathan Finn | Director | A | +62,500 deriv. | — |
| 2023-11-15 | Jonathan Finn | Director | A | +62,500 deriv. | — |
| 2023-06-20 | Gregory L Weaver | EVP & CFO | Buy | +50,000 | +$48.50K |
| 2023-06-05 | Gregory L Weaver | EVP & CFO | A | +2,600,000 deriv. | — |
| 2023-05-05 | H. Lawrence Remmel | Director | A | +125,000 deriv. | — |
| 2023-05-05 | Shu-Chih Chen | Director | A | +125,000 deriv. | — |
| 2023-05-05 | Stephen J Galli | Director | A | +125,000 deriv. | — |
| 2023-05-05 | Gregory L Weaver | Director | A | +125,000 deriv. | — |
| 2023-05-05 | Richard I Steinhart | Director | A | +125,000 deriv. | — |
| 2023-03-06 | Steven C Quay | President & CEO | A | +1,873,100 deriv. | — |
| 2023-03-06 | Kyle Guse | CFO, Gen Counsel and Secretary | A | +557,900 deriv. | — |
| 2022-05-16 | Richard I Steinhart | Director | A | +50,000 deriv. | — |
| 2022-05-16 | Stephen J Galli | Director | A | +50,000 deriv. | — |
| 2022-05-16 | Gregory L Weaver | Director | A | +50,000 deriv. | — |
| 2022-05-16 | Shu-Chih Chen | Director | A | +50,000 deriv. | — |
| 2022-05-16 | H. Lawrence Remmel | Director | A | +50,000 deriv. | — |
| 2022-02-28 | Steven C Quay | President & CEO | A | +1,900,000 deriv. | — |
| 2022-02-28 | Kyle Guse | CFO, Gen Counsel and Secretary | A | +746,667 deriv. | — |
| 2021-07-07 | Gregory L Weaver | Director | MIXED | — | −$599.83K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Mark James Daniel | Chief Financial Officer | 63,000 | $155.61K |
| Steven C Quay | President & CEO | 24,522 | $60.57K |
| Jonathan Finn | Director | 11,666 | $28.82K |
| Shu-Chih Chen | Director | 11,483 | $28.36K |
| H. Lawrence Remmel | Director | 10,684 | $26.39K |
| Stephen J Galli | Director | 10,006 | $24.71K |
| Richard I Steinhart | Director | 10,000 | $24.70K |
| Tessa Cigler | Director | 10,000 | $24.70K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATOS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.